WO2006041641A3 - Therapeutic agents with decreased toxicity - Google Patents
Therapeutic agents with decreased toxicity Download PDFInfo
- Publication number
- WO2006041641A3 WO2006041641A3 PCT/US2005/033952 US2005033952W WO2006041641A3 WO 2006041641 A3 WO2006041641 A3 WO 2006041641A3 US 2005033952 W US2005033952 W US 2005033952W WO 2006041641 A3 WO2006041641 A3 WO 2006041641A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agents
- decreased toxicity
- toxicity
- methods
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0516577-6A BRPI0516577A (en) | 2004-10-05 | 2005-09-22 | therapeutic agents with reduced toxicity |
EP05810079A EP1796718A2 (en) | 2004-10-05 | 2005-09-22 | Therapeutic agents with decreased toxicity |
JP2007535700A JP2008515889A (en) | 2004-10-05 | 2005-09-22 | A therapeutic agent with reduced toxicity |
MX2007003907A MX2007003907A (en) | 2004-10-05 | 2005-09-22 | Therapeutic agents with decreased toxicity. |
CA002583137A CA2583137A1 (en) | 2004-10-05 | 2005-09-22 | Therapeutic agents with decreased toxicity |
AU2005294723A AU2005294723A1 (en) | 2004-10-05 | 2005-09-22 | Therapeutic agents with decreased toxicity |
IL182261A IL182261A0 (en) | 2004-10-05 | 2007-03-28 | Therapeutic agents with decreased toxicity |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61650704P | 2004-10-05 | 2004-10-05 | |
US60/616,507 | 2004-10-05 | ||
US64153405P | 2005-01-05 | 2005-01-05 | |
US60/641,534 | 2005-01-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006041641A2 WO2006041641A2 (en) | 2006-04-20 |
WO2006041641A3 true WO2006041641A3 (en) | 2006-06-29 |
Family
ID=36051453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/033952 WO2006041641A2 (en) | 2004-10-05 | 2005-09-22 | Therapeutic agents with decreased toxicity |
Country Status (11)
Country | Link |
---|---|
US (2) | US20060073152A1 (en) |
EP (1) | EP1796718A2 (en) |
JP (1) | JP2008515889A (en) |
KR (1) | KR20070073886A (en) |
AU (1) | AU2005294723A1 (en) |
BR (1) | BRPI0516577A (en) |
CA (1) | CA2583137A1 (en) |
IL (1) | IL182261A0 (en) |
MX (1) | MX2007003907A (en) |
RU (1) | RU2007116973A (en) |
WO (1) | WO2006041641A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2544527T3 (en) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease |
ZA200603619B (en) | 2003-11-06 | 2008-10-29 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2006132670A2 (en) * | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
AU2006269422B2 (en) | 2005-07-07 | 2012-12-06 | Seagen Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
US9845355B2 (en) | 2007-07-16 | 2017-12-19 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
PL2474557T3 (en) | 2007-07-16 | 2015-02-27 | Genentech Inc | Anti-CD79b antibodies and immunoconjugates and methods of use |
US20090035848A1 (en) * | 2007-08-03 | 2009-02-05 | Robert Hickey | Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products |
RU2553566C2 (en) | 2008-01-31 | 2015-06-20 | Дженентек, Инк. | ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM |
CA2718942A1 (en) * | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
ES2594893T3 (en) * | 2009-12-16 | 2016-12-23 | Abbvie Biotherapeutics Inc. | Anti HER2 antibodies and their uses |
US20130066055A1 (en) * | 2011-04-21 | 2013-03-14 | Bayer Intellectual Property Gmbh | New binder-drug conjugates (adcs) and use thereof |
JP2014521060A (en) | 2011-06-28 | 2014-08-25 | コーニンクレッカ フィリップス エヌ ヴェ | Means for testing body fluids |
US20130165628A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Double Binding Constructs |
WO2014210029A1 (en) * | 2013-06-24 | 2014-12-31 | Riogin Corporation | Double binding constructs |
WO2015030539A1 (en) | 2013-08-30 | 2015-03-05 | Aprilbio Co., Ltd | An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof |
PL3262071T3 (en) | 2014-09-23 | 2020-08-10 | F. Hoffmann-La Roche Ag | Method of using anti-cd79b immunoconjugates |
CN111164104A (en) | 2017-08-09 | 2020-05-15 | 麻省理工学院 | Albumin binding peptide conjugates and methods thereof |
KR20210095781A (en) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety |
WO2023092733A1 (en) * | 2021-11-25 | 2023-06-01 | 苏州慧疗生物医药科技有限公司 | Cyclic polypeptide carrier for efficient delivery of nucleic acid, and variant thereof |
WO2024061224A1 (en) * | 2022-09-20 | 2024-03-28 | 普米斯生物技术(珠海)有限公司 | Anti-her2 antibodies and use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991001743A1 (en) * | 1989-08-01 | 1991-02-21 | Cemu Bioteknik Ab | Stabilized protein or peptide conjugates |
US6387371B1 (en) * | 1988-01-12 | 2002-05-14 | Genentech, Inc. | Monoclonal antibodies directed to the HER2 receptor |
WO2003031464A2 (en) * | 2001-10-10 | 2003-04-17 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
WO2004032828A2 (en) * | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3561444A (en) * | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
US3703173A (en) * | 1970-12-31 | 1972-11-21 | Ted A Dixon | Nebulizer and tent assembly |
US3862925A (en) * | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US3842067A (en) * | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
JPS5726506B2 (en) * | 1974-03-08 | 1982-06-04 | ||
US4105603A (en) * | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4635627A (en) * | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
US4624251A (en) * | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
US4970198A (en) * | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US5079233A (en) * | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
LU91067I2 (en) * | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ATE168014T1 (en) * | 1991-11-08 | 1998-07-15 | Somatogen Inc | HEMOGLOBINS AS A DRUG DELIVERY SYSTEM |
US5767237A (en) * | 1993-10-01 | 1998-06-16 | Teikoku Hormone Mfg. Co., Ltd. | Peptide derivatives |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5780054A (en) * | 1996-01-17 | 1998-07-14 | University Of British Columbia | Methods for increasing the circulation half-life of protein-based therapeutics |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US6632979B2 (en) * | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20030009395A1 (en) * | 2001-07-06 | 2003-01-09 | Yu Philip Shi-Lung | Method and apparatus for providing information regarding a product |
ES2401428T3 (en) * | 2002-04-10 | 2013-04-19 | Genentech, Inc. | Anti-HER2 antibody variants |
US20040032828A1 (en) * | 2002-08-16 | 2004-02-19 | Cellglide Technologies Corp. | Service management in cellular networks |
ZA200603619B (en) * | 2003-11-06 | 2008-10-29 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
-
2005
- 2005-09-22 CA CA002583137A patent/CA2583137A1/en not_active Abandoned
- 2005-09-22 AU AU2005294723A patent/AU2005294723A1/en not_active Abandoned
- 2005-09-22 MX MX2007003907A patent/MX2007003907A/en not_active Application Discontinuation
- 2005-09-22 JP JP2007535700A patent/JP2008515889A/en not_active Withdrawn
- 2005-09-22 KR KR1020077010255A patent/KR20070073886A/en not_active Application Discontinuation
- 2005-09-22 RU RU2007116973/13A patent/RU2007116973A/en not_active Application Discontinuation
- 2005-09-22 WO PCT/US2005/033952 patent/WO2006041641A2/en active Application Filing
- 2005-09-22 US US11/233,256 patent/US20060073152A1/en not_active Abandoned
- 2005-09-22 EP EP05810079A patent/EP1796718A2/en not_active Withdrawn
- 2005-09-22 BR BRPI0516577-6A patent/BRPI0516577A/en not_active Application Discontinuation
-
2006
- 2006-09-25 US US11/535,027 patent/US20090123376A1/en not_active Abandoned
-
2007
- 2007-03-28 IL IL182261A patent/IL182261A0/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6387371B1 (en) * | 1988-01-12 | 2002-05-14 | Genentech, Inc. | Monoclonal antibodies directed to the HER2 receptor |
WO1991001743A1 (en) * | 1989-08-01 | 1991-02-21 | Cemu Bioteknik Ab | Stabilized protein or peptide conjugates |
WO2003031464A2 (en) * | 2001-10-10 | 2003-04-17 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
WO2004032828A2 (en) * | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
Non-Patent Citations (3)
Title |
---|
DENNIS M S ET AL: "Albumin binding as a general strategy for improving the pharmacokinetics of proteins", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 277, no. 38, 20 September 2002 (2002-09-20), pages 35035 - 35043, XP002285300, ISSN: 0021-9258 * |
FRANCISCO J A ET AL: "cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 102, no. 4, 15 August 2003 (2003-08-15), pages 1458 - 1465, XP002280965, ISSN: 0006-4971 * |
MAO WEIGUANG ET AL: "EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 781 - 788, XP002343724, ISSN: 0008-5472 * |
Also Published As
Publication number | Publication date |
---|---|
EP1796718A2 (en) | 2007-06-20 |
JP2008515889A (en) | 2008-05-15 |
MX2007003907A (en) | 2007-05-21 |
IL182261A0 (en) | 2007-07-24 |
WO2006041641A2 (en) | 2006-04-20 |
CA2583137A1 (en) | 2006-04-20 |
US20060073152A1 (en) | 2006-04-06 |
BRPI0516577A (en) | 2008-09-16 |
US20090123376A1 (en) | 2009-05-14 |
AU2005294723A1 (en) | 2006-04-20 |
KR20070073886A (en) | 2007-07-10 |
RU2007116973A (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006041641A3 (en) | Therapeutic agents with decreased toxicity | |
WO2005067980A3 (en) | Design of therapeutics and therapeutics | |
WO2006036371A3 (en) | Combination therapy | |
WO2004021968A3 (en) | Solution for ungual application | |
EP2230254A3 (en) | Anti-IGFR1 antibody therapeutic combinations | |
WO2006034373A8 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
WO2005120461A3 (en) | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof | |
WO2005067898A3 (en) | Improved sustained release compositions for pulmonary administration of insulin | |
WO2006095029A3 (en) | Di-polymer protein conjugates and processes for their preparation | |
WO2005016286A3 (en) | Pyrazine modulators of cannabinoid receptors | |
WO2007113648A3 (en) | Ctla4 antibody combination therapy | |
WO2007146248A3 (en) | Stable laquinimod preparations | |
WO2003074551A3 (en) | Conjugates of therapeutic or cytotoxic agents and biologically active peptides | |
WO2005112633A3 (en) | Compounds and compositions for delivering active agents | |
WO2007019865A3 (en) | Therapy with cd4 binding peptides and radiation | |
WO2006085932A3 (en) | Anti-viral uses of borinic acid complexes | |
WO2004001009A3 (en) | Apo-2 ligand/trail variants and uses thereof | |
WO2007048027A3 (en) | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent | |
WO2006007671A3 (en) | Therapeutically combinations | |
WO2006091542A3 (en) | Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier | |
WO2006009874A3 (en) | Methods and compositions for treatment of excess nitric oxide or cyanide toxicity | |
WO2006088814A3 (en) | Dosage form and method for sustained release of a substituted pyrazine compound | |
WO2007133944A3 (en) | Topical administration of acyclovir | |
WO2006124753A3 (en) | Antipyretic agents against vr1-antagonist-induced increases in body temperature | |
WO2008044076A3 (en) | Therapy targeting cathepsin s |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 554161 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 182261 Country of ref document: IL Ref document number: 2005294723 Country of ref document: AU Ref document number: 2370/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/003907 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2583137 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007535700 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005810079 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005294723 Country of ref document: AU Date of ref document: 20050922 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005294723 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/03478 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077010255 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007116973 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580041758.9 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005810079 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0516577 Country of ref document: BR |